Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The new site marks the company’s first operation in the region
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
76 of 180 long COVID-associated genes also linked to ME
Subscribe To Our Newsletter & Stay Updated